52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B

• Teerha Piratvisuth ,

  * E-mail: teerha.p@psu.ac.th

  Affiliation NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, Songklanagarind Hospital, Hat-Yai, Songkhla, Thailand

  ⨯
• Piyawat Komolmit,

  Affiliation Division of Gastroenterology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand

  ⨯
• Tawesak Tanwandee,

  Affiliation Siriraj Hospital, Bangkok, Thailand

  ⨯
• Wattana Sukeepaisarnjaroen,

  Affiliation Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand

  ⨯
• Henry L. Y. Chan,

  Affiliation Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong S.A.R

  ⨯
• Mário G. Pessôa,

  Affiliation Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

  ⨯
• Eduardo Fassio,

  Affiliation Hospital Nacional Prof. Alejandro Posadas, Buenos Aires, Argentina

  ⨯
• Suzane K. Ono,

  Affiliation Departamento de Gastroenterologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

  ⨯
• Fernando Bessone,

  Affiliation Catedra de Clınica Medica, Universidad Nacional de Rosario, Rosario, Antigua and Barbuda

  ⨯
• Jorge Daruich,

  Affiliation Hospital de Clínicas San Martín, University of Buenos Aires, Buenos Aires, Argentina

  ⨯
• Stefan Zeuzem,

  Affiliation Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt am Main, Germany

  ⨯
• Hugo Cheinquer,

  Affiliation Gastroenterology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil

  ⨯
• Rashidkhan Pathan,

  Affiliation Novartis Pharmaceuticals, East Hanover, New Jersey, United States of America

  ⨯
• Yuhong Dong,

  Affiliation Novartis Pharma AG, Basel, Switzerland

  ⨯
• Aldo Trylesinski

  Affiliation Novartis Pharma AG, Basel, Switzerland

  ⨯